Fig. 3
From: The global impact and cost-effectiveness of a melioidosis vaccine
Geography-specific optimal cost-effective vaccination strategy and cost-effectiveness results of base case analysis by region. a Optimal cost-effective vaccination strategy by geography. b Incremental cost-effectiveness ratio for each vaccine strategy by region. Strategies are vaccinating (i) people over 45 years with chronic renal disease (Vac 1), (ii) people aged over 45 years with diabetes (Vac 2), (iii) people aged over 45 years with diabetes and/or chronic renal disease (Vac 3) and (iv) people aged over 45 years (Vac 4)